Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01415505 · ClinicalTrials.gov registry record · Phase 3
Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension
A Phase 3 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 812
- Enrollment target
NCT01415505: Completed Phase 3 study, sponsored by Forest Laboratories.
NCT01415505 is a Phase 3 study that has completed, run by Forest Laboratories. The registered enrollment target is 812 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01415505, a Phase 3 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 812 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of nebivolol and valsartan given as a free tablet combination in patient with stage 1 or stage 2 essential hypertension.
Interventions
- DRUG Nebivolol, Valsartan and Hydrochlorothiazide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 812 participants |
| Start Date | 2011-08 |
| Est. Completion | 2013-04 |
| Phase | Phase 3 |
What the finished NCT01415505 record still lists
NCT01415505 is an interventional study that assigns participants to a tested intervention. The registered 812 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which Nebivolol, Valsartan and Hydrochlorothiazide is the first listed.
NCT01415505 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01415505 about?
NCT01415505 is a clinical study titled "Combination of Nebivolol and Valsartan Given as Free Tablets for Stage 1 or Stage 2 Hypertension". The purpose of this study is to evaluate the safety and tolerability of nebivolol and valsartan given as a free tablet combination in patient with stage 1 or stage 2 essential hypertension.
What is the current status of trial NCT01415505?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 812 participants. The study started on 2011-08. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01415505?
The interventions under investigation include: Nebivolol, Valsartan and Hydrochlorothiazide (DRUG).
Who is sponsoring clinical trial NCT01415505?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01415505's enrollment target sits among peer trials
812 408th of 2000 higher than 1,593 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05519085 · 810 participants · Phase 3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- NCT07218029 · 815 participants · Phase 3
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
- NCT06529094 · 808 participants · NA
Implementing a Decision Support Tool to Prevent Community-Acquired Pressure Injury in Spinal Cord Injury (SCI) in the Spinal Cord Injury Clinic
- NCT04846959 · 818 participants
Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia